ACE-031
ACE-031 from the Nexus Healing & Recovery catalog, supplied for controlled in-vitro research workflows.
Ships from the US with tracking.
Catalog active: Catalog pricing is active. Live warehouse counts are not published.
- Lot-specific COA
- HPLC + MS fields
- Batch archived
For in-vitro research use only. Not for human consumption.
ACE-031 is a soluble activin receptor type IIB (ActRIIB) construct fused to an IgG1-Fc domain. In research systems, it acts as a ligand trap by binding and sequestering myostatin, activin, GDF-11, and other TGF-β superfamily ligands that normally inhibit muscle growth. This mechanism makes ACE-031 relevant to laboratory studies of myostatin signaling and muscle-hypertrophy pathway models.
ACE-031 definition
ACE-031 is a soluble activin receptor type IIB (ActRIIB) fused to an IgG1-Fc domain. It functions as a ligand trap, binding and sequestering myostatin, activin, GDF-11, and other TGF-β superfamily ligands that normally inhibit muscle growth. This mechanism makes it a tool for studying myostatin signaling and muscle hypertrophy pathways.
No sequence is listed in the current catalog record for this product.
- CAS
- N/A (fusion protein)
- MW
- 90000 g/mol
- Sequence
- Not listed
- Half-life
- Not listed
- Formula
- Not listed
- Purity
- 99.84%
- Form
- Not listed
- Class
- Healing & Recovery
The dossier.
Compound Overview
ACE-031 is a soluble activin receptor type IIB (ActRIIB) construct fused to an IgG1-Fc domain. In research systems, it acts as a ligand trap by binding and sequestering myostatin, activin, GDF-11, and other TGF-β superfamily ligands that normally inhibit muscle growth. This mechanism makes ACE-031 relevant to laboratory studies of myostatin signaling and muscle-hypertrophy pathway models.
Research Background & Published Literature
ACE-031 was developed by Acceleron Pharma and is discussed in clinical-trial literature involving Duchenne muscular dystrophy research cohorts. Published work in Muscle & Nerve and related journals examined muscle mass and strength parameters in preclinical models. This background is provided for mechanistic research context only and does not indicate therapeutic, human-use, or veterinary-use approval for Nexus ACE-031.
For additional context on mechanism of action, signaling pathways, and controlled experimental applications, researchers can review the peer-reviewed literature below:
Researchers reviewing the literature around this compound can use the peer-reviewed resources below for additional context on mechanism of action, signaling pathways, and controlled laboratory research applications:
Storage, Handling & Stability Guidelines
Use the applicable lot/source record for storage of unopened material. Any diluent selection, preparation, temperature, aliquoting, or post-reconstitution hold conditions must be established by a qualified laboratory under a validated SOP; this page does not establish a stability window.
- Limit ambient-temperature handling time to help preserve compound integrity.
- Reseal vials promptly after each withdrawal to reduce moisture exposure.
- Wear appropriate personal protective equipment and follow institutional chemical safety protocols at all times.
- For traceability, label aliquots with compound name, concentration, reconstitution date, and operator initials.
Quality Assurance & Lab Verification
A finalized public Certificate of Analysis is available for this catalog item. Review the public COA for the applicable lot. Lot-specific identifiers, assay values, and methods are maintained in that record and are not repeated in this product dossier.
Shipping
Orders ship within the United States via USPS; international orders are not accepted. Laboratories should follow their validated SOP together with any handling fields published for the represented product or lot; no universal prepared-solution condition is inferred here.
Compound details.
- Molecular Weight
- ~90,000 g/mol (fusion protein)
- Class
- ActRIIB-Fc Fusion Protein / Myostatin Inhibitor
Research context.
ACE-031 was developed by Acceleron Pharma and studied in clinical trials for Duchenne muscular dystrophy. Published data in Muscle & Nerve and other journals examined its effects on muscle mass and strength parameters in preclinical models.
Verification standard.
Certificate information is lot-specific. A finalized public record shows only the methods, fields, and results present for that named lot. A pending certificate state exposes no assay values and must not be interpreted as analytical verification. Review Nexus lab verification.
Analytical record.
- Reported HPLC purity
- 99.84%
- Retention time
- 13.80 min
- Observed mass
- 57250.00 Da
- Batch
- APX-2026-0412-A
The normalized Certificate of Analysis publishes only the lot-specific fields represented in the public record. It is not an originating laboratory report or raw instrument file.
View certificate of analysis - batch APX-2026-0412-A- Sequence
- Not listed
- Model preview
- Unavailable
Molecular model preview is unavailable for this catalog record.
The chemistry.
Static molecular fallback shown because this catalog record does not include a sequence suitable for the amino-acid viewer.
Related research compounds
Comparable catalog records with published variants and certificate status.
- Healing & RecoveryVerified batchBPC 157PriceFrom $30.99Formats4 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 137525-51-0View product - Healing & RecoveryVerified batchTB500 (Thymosin B4 Acetate)PriceFrom $30.99Formats4 sizes
Compare size options, price, and certificate status before opening the product record.
CAS 77591-33-4View product - Healing & RecoveryCertificate pendingTB500 (FRAG)Price$60.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product - Healing & RecoveryCertificate pendingBPC 2mg + TB 2mgPrice$54.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product - Healing & RecoveryVerified batchBPC 5mg + TB 5mgPrice$80.99Formats1 size
Compare size options, price, and certificate status before opening the product record.
View product
ACE-031 research FAQ.
What is ACE-031 used for in research?
ACE-031 is supplied for controlled in-vitro research workflows in the Healing & Recovery category. It is not labeled for human or veterinary use.
Does ACE-031 have a finalized analytical record?
ACE-031 has a finalized Nexus Lab Verified record that reports 99.84% HPLC area-percent purity for the represented batch. Other fields are shown only where present.
Which ACE-031 variants are published?
Published Nexus variants include 1mg.
Does ACE-031 include a COA?
Yes. The current Nexus record links ACE-031 to finalized batch APX-2026-0412-A.